Skip to main content
. 2023 Jun 27;12(1):2227510. doi: 10.1080/2162402X.2023.2227510

Figure 4.

Figure 4.

In vitro effects of TLR3 agonists on the antigen cross-presentation by de-iniDcs of different genotypes. (a) Scheme of the in vitro antigen cross-presentation assay. Inducible immortalized dendritic cell (iniDC) precursors were differentiated to DCs (de-iniDC) in the absence of dexamethasone or doxycycline (Dex/Dox) for 3 days. De-iniDcs were pretreated with the indicated TLR3 agonists (poly(I:C) (pIC) and poly(A:U) (pAU) at 2 and 20 µg/mL, and TL-532 at 20 and 200 µg/mL.) for 16 h. For measuring antigen cross-presentation, soluble ovalbumin (OVA) was added to the de-iniDC culture and the de-iniDcs were incubated for additional 6 h before wash and co-culture with B3Z hybridoma T cells. Eighteen hours later, the co-culture supernatants were collected for the quantification of IL2 by ELISA. (b) IL2 concentrations were calculated based on standard curves and normalized to untreated wild-type controls. One representative experiment out of three replicates is reported as aligned dot plots (mean ± SD, n = 5). Statistical significance was calculated by means of two-way ANOVA with Dunnett’s multiple comparisons test.